Trial Information
Iscar for Supplemental Care in Stage IV Lung Cancer
See Brief Summary
Inclusion Criteria:
- Stage IV NSCLC patients who receive standard chemotherapy
Exclusion criteria:
- Known allergy to Viscum Album L.
- Concomitant use of other mistletoe products
- Concomitant use of mushroom glucan and proteoglycan extracts
- Concomitant use of thymus extract products
- Inability to self-report quality of life utilizing assessment tools
- Ongoing steroid or ACTH therapy
- Co-morbid immunocompromised state
- Pregnancy
- Participation in other clinical trials
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Principal Investigator
Steven Rosenzweig, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Jefferson Medical College of Thomas Jefferson University
Authority:
United States: Food and Drug Administration
Study ID:
R21 AT001020-01
NCT ID:
NCT00079794
Start Date:
September 2001
Completion Date:
February 2004
Related Keywords:
- Lung Cancer
- lung cancer
- herbal medicine
- non-small cell cancer
- Iscar
- mistletoe
- Lung Neoplasms
Name | Location |
|---|
| Thomas Jefferson University |
Philadelphia, Pennsylvania 19107-6541 |
